Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Lu AE04621 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lundbeck A/S
- 16 Dec 2016 Status changed from recruiting to completed.
- 20 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 11 Jan 2016 New trial record